Provided by Tiger Trade Technology Pte. Ltd.

PharmaCyte Biotech, Inc.

0.8901
-0.0462-4.93%
Post-market: 0.89430.0042+0.47%19:52 EST
Volume:172.03K
Turnover:158.21K
Market Cap:9.02M
PE:-0.80
High:0.9420
Open:0.9300
Low:0.8811
Close:0.9363
52wk High:1.90
52wk Low:0.6300
Shares:10.13M
Float Shares:8.93M
Volume Ratio:0.59
T/O Rate:1.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1141
EPS(LYR):3.19
ROE:-17.68%
ROA:-4.76%
PB:0.25
PE(LYR):0.28

Loading ...

Dec 18, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dec 05, 2025

Major Issues Report

Form 8-K - Current report
Nov 18, 2025

Major Issues Report

Form 8-K/A - Current report: [Amend]
Oct 31, 2025

Major Issues Report

Form 8-K - Current report
Sep 15, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 05, 2025

Major Issues Report

Form 8-K - Current report
Aug 18, 2025

Major Issues Report

Form 8-K - Current report
Aug 09, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Apr 24, 2025

Major Issues Report

Form 8-K - Current report
Mar 17, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 26, 2025

Major Issues Report

Form 8-K - Current report
Dec 13, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dec 04, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 13, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Sep 17, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 13, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
May 31, 2024

Beneficial Ownership Change

Form SC 13D - General statement of acquisition of beneficial ownership
May 23, 2024

Major Issues Report

Form 8-K - Current report
May 02, 2024

Major Issues Report

Form 8-K - Current report
Mar 18, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]